Quality of Life Kinoko Platinum AHCC 750 Mg 60 Ct by Quality of Life

Product Information

Judith A. Smith 1,2* Anjali A. Gaikwad 1 Lata Mathew 1 Barbara Rech 3 Jonathan P. Faro 4 Joseph A. Lucci III 1,2 Yu Bai 5 Randall J. Olsen 6 Teresa T. Byrd 1 of Obstetrics, Gynecology and Reproductive Sciences, UT Health McGovern Medical School, Houston, TX, United States After 12 weeks of supplementation, the percentage change in alanine aminotransferase (ALT) levels was significantly different between the placebo and both AHCC groups (1 g of AHCC ® and 3 g of AHCC ®). Serum levels of tumor necrosis (p < 0.05) and interleukin-1β ( p < 0.01) were significantly lower, while those of adiponectin were higher in both AHCC ® groups than in the placebo group (p < 0.01). AHCC ® supplementation for 12 weeks may improve the levels of liver enzymes and circulating pro-inflammatory and anti-inflammatory cytokines in patients with alcohol-induced mildly elevated liver enzyme levels. The liver enzyme levels, lipid profiles, insulin resistance, and scores on fatigue and stress-related questionnaires did not show significant differences between the groups (p < 0.05); however, cytokine levels did show significant differences (TNF-α, IL-1β, and adiponectin, p < 0.05). Comparing the percentage changes at 12 weeks as analyzed by a paired t-test, a decrease in liver enzymes in both AHCC groups and a change in IL-1β and adiponectin in the 1-g AHCC ® group were found to be statistically significant. When analyzed with ANOVA, the percentage changes of serum levels of inflammatory cytokines, such as TNF-α (p < 0.05) and IL-1β (p < 0.01), were lower in the AHCC ® supplementation groups than in the placebo group. Serum levels of adiponectin were higher in both AHCC ® groups than in the placebo group (p < 0.05). Women who have taken commercial supply of AHCC within the past 6 months on their own. Those who have been participating in the AHCC 1 g day pilot study are eligible to enroll in this study.

If you breach these conditions and we take no action, we will still be entitled to use our rights and remedies in any other situation where you breach these conditions. Governing Law and Jurisdiction Objective: There is currently no effective medicine or supplement for clearance of high risk- human papillomavirus (HR-HPV) infections. We have taken a systematic approach evaluating the potential use of AHCC supplementation to support clearance of HR-HPV infections. The primary objective of this research was to evaluate AHCC supplementation to modulation of the host immune system to clear HR-HPV infections from bench to bedside. VEGAN WITH NO FILLERS, BINDERS OR ADDITIVES. At Time Health we believe in clean nutrition which is why you won’t find any nasty stuff in our products including any binders, fillers or additives, unlike some of our competitors. AHCC is a proprietary, standardized extract of cultured lentinula edodes mycelia (AHCC ®, Amino Up, Ltd., Sapporo, Japan) that was developed in Japan in 1992; the compound is primarily composed of α-glucan components. Several animal and human studies have reported a variety of therapeutic effects, including antioxidant and anticancer activities and modulation of the immune system to prevent the infectious processes of both viral and bacterial infections ( 9– 14). In clinical studies, AHCC has demonstrated the benefit to decrease the risk of infection and ameliorate symptoms of existing infections ( 11).The studies involving human participants were reviewed and approved by the University of Texas Health Sciences Center Institutional Review Board. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article. Author Contributions

HPV samples were evaluated initially with HPV E6/E7 RNA testing (APTIMA, Hologic, Marlborough, MA, USA) at the UTHealth McGovern Medical School Molecular Pathology laboratory. HPV RNA-negative results were confirmed with COBAS HPV DNA testing (Roche Molecular Systems, Inc., Branchburg, NJ, USA) at Methodist Molecular Pathology laboratory to detect the presence of HPV DNA and rule out latent HPV infections. Immune Marker and Natural Killer Cell Assays There are limited effective treatment options for clearing HR-HPV infections; majority being local treatment modalities is to alleviate symptoms and remove symptomatic lesions that often reoccur. Fortunately, most HR-HPV infections are cleared within 6–18 months on their own without interventions; only ~10% of women will suffer from persistent HR-HPV infections ( 15, 24). To date, there is no readily available effective systemic interventions to clear HR-HPV infections. Currently prevention of HR-HPV infections with the HPV vaccine nine-valent product before exposure to HPV has demonstrated the best potential for eliminating HR-HPV infections. However, these vaccines have little benefit in those already infected with HR-HPV infections. The presented bench-to-bedside research provides step-wise data to support the hypothesis that AHCC supplementation modulates host immune system, specifically via suppression of elevated IFNβ levels, to effectively clear chronic, persistent HR-HPV infections. After observing elimination of HR-HPV in vitro in the panel of human cervical cancer cell lines, animal studies were completed that also demonstrated successful, durable elimination of HR-HPV after completing AHCC supplementation. Finally, in two “proof of concept” pilot studies of daily AHCC supplementation successful elimination of HR-HPV was achieved that was durable response. Both the animal and human data suggests the mechanism AHCC supplementation supports the host immune system to clear HPV infections is attributed to the modulation of the expression and signaling of IFNβ that is known to be elevated in chronic viral infections (16, 17).Results: Fifty women with high-risk HPV were enrolled, and 41 completed the study. Fourteen (63.6%) of the 22 patients in the AHCC supplementation arm were HPV RNA/HPV DNA negative after 6 months, with 64.3% (9/14) achieving a durable response defined as being HPV RNA/HPV DNA negative 6 months off supplementation. On the placebo arm, two (10.5%) of 19 patients were HPV negative at 12 months. In the twelve placebo arm patients who elected to continue on the unblinded study, 50% (n = 6) were HPV RNA/HPV DNA negative after 6 months of AHCC supplementation. At the time of completion of the study, there were a total of 34 patients (22 blinded and 12 unblinded) who had received AHCC supplementation with an overall response rate of 58.8% that cleared HPV persistent infections. At the time of enrollment, the mean IFN-β level was 60.5 ± 37.6 pg/ml in women with confirmed persistent HPV infections. Suppression of IFN-β to less than 20 pg/ml correlated with an increase in T lymphocytes and IFN-γ and durable clearance of HPV infections in women who received AHCC supplementation. IMPORTANT: If this is your first time taking this product, you may want to start with half a capsule per day for a short while. We recommend starting on the lowest possible dose and gradually increasing as your body gets used to it. AminoUp’s vision is to see AHCC become a household name as a daily nutritional supplement for immune maintenance. Currently, AHCC is shipped to an estimated 150,000 people in 40 countries worldwide, and demand is growing. The stained cells were acquired using LSR II (BD Biosciences), and Diva software was used for analysis. With the use of forward and side scatter, the lymphocyte population was gated on low side scatter and CD45 bright population while acquiring the 50,000 gated events. The NK cell population was then identified as (CD3 negative, CD 2, CD56C, and CD7 positive) cells. The percent of T cells and NK cells from the lymphocyte gate was obtained for the final analysis. Statistical Analysis Our approach is to explore new possibilities from the power of nature, to induce the natural potential that we have in our body and to bring out the innate strength in all living things,” says Kitadate.

I just wanted to give a testimonial about using your wonderful AHCC product. My name is Alina and I have been battling bile duct and liver cancer for the past 4 years. Over those past 4 years and 6 months I have taken your AHCC product daily along with my scheduled weekly conventional chemo and radiation treatments. During this time I have endured the following. 65 chemo treatments and 15 Proton radiation treatments with NO HAIR LOSS. I maintained a great appetite without the use of a doctor prescribed medication to increase my appetite. Blood work continues to be good on a weekly basis and energy level has been good and I am able to take lengthy daily walks of at least 1 hour. Weight has been maintained at a good level. All of the time I know that all of the items mentioned above would not be able without the daily usage of your AHCC product! AHCC continues to be a part of my daily routine and has proven to work for me! (*)" Alina T - Sherman, TX"The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Publisher’s Note POTENCY. 100% natural Mushroom Complex 6 MAXIMUM STRENGTH is an equal mix of six different mushrooms, Chaga, Cordyceps, Shiitake, Reishi, Lions mane and Maitake giving a diverse, high potency, complete mushroom formula. AminoUp’s leading supplement, AHCC, was launched in 1987, following an evaluation of more than 100 different mushroom species, and systematically tested for optimized manufacturing. UK MADE & HIGH QUALITY. This product is manufactured in the UK to GMP standards, ensuring the highest quality. JS served as principal investigator of the clinical trial and was responsible for study concept, protocol design, data analysis, clinical interpretation of data, writing, and finalization of the manuscript. AG, LM, and BR served as the primary research team responsible for patient screening, clinic visits, sample collection, and analysis and participated in the writing and review of the manuscript. JF served as a clinical collaborator on this study and participated in protocol design, clinical interpretation of data, and final review of the manuscript. JL served as a clinical collaborator on this study and participated in the clinical interpretation of the data and final review of the manuscript. YB served as a research collaborator participating in the interpretation of the sample of analysis, protocol design, and review of the final manuscript. RO served as a research collaborator participating in the interpretation of the sample of analysis and implications for future monitoring assays. He participated in the review and finalization of the manuscript. TB served as a clinical collaborator on this study and participated in protocol design, clinical interpretation of data, and final review of the manuscript. All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication. Funding

In the growth inhibition assays supplementation with AHCC for 72 h did not achieve any cell growth inhibition in any of the four human cervical cancer cell lines tested at clinically relevant concentration of 0.42 mg/mL. However, potential direct cytotoxicity was observed the concentration to achieve 50% growth inhibition (IC 50), for AHCC ranged from 2.3 to 4 mg/mL in the four human cervical cancer cell lines however this is well above clinically achievable systemic concentrations. These results are summarized in Table 1. For example, ‘superbugs’, bacteria that are resistant to all available antibiotics, are expected to be responsible for more deaths than cancer by 2050, according to a review commissioned by the UK Government. Homma says that AHCC may help to support the immune system to enable the body to better fight infection, and potentially to reduce the use of strong antibiotics.

Discussion

Your relationship with Time Health Ltd is governed by and construed in accordance with the laws of the United Kingdom. You agree, as we do, to submit to the non-exclusive jurisdiction of the Courts of the United Kingdom. All patients enrolled were included in safety analysis for adverse events. Overall, no study patients reported greater than grade 1 toxicity on either placebo or the AHCC supplement arm. AHCC was well tolerated compared to placebo.